We are live on ! Find out more
EA

Emerald Advisers Portfolio holdings

AUM $4.25B
1-Year Est. Return 141.71%
This Fund
S&P 500
This Quarter Est. Return
+6.36%
1 Year Est. Return
+141.71%
3 Year Est. Return
+486.97%
5 Year Est. Return
+675.33%
10 Year Est. Return
+5,134.3%
AUM
$1.94B
AUM Growth
-$6.24M
Cap. Flow
-$8.36M
Cap. Flow %
-0.43%
Top 10 Hldgs %
18.4%
Holding
264
New
14
Increased
88
Reduced
101
Closed
15

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$20.5M
2
CELH icon
Celsius Holdings
CELH
+$20M
3
AHCO icon
AdaptHealth
AHCO
+$19.3M
4
NOG icon
Northern Oil and Gas
NOG
+$18.9M
5
PRVA icon
Privia Health
PRVA
+$16.5M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$24.9M
2
AVNT icon
Avient
AVNT
+$21.7M
3
ONTO icon
Onto Innovation
ONTO
+$20M
4
ALKS icon
Alkermes
ALKS
+$19.3M
5
VC icon
Visteon
VC
+$15.9M

Sector Composition

Rank Sector Weight
1 Healthcare 30.94%
2 Industrials 16.43%
3 Consumer Discretionary 13.81%
4 Technology 13.49%
5 Financials 10.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXPO icon
26
Exponent
EXPO
$3.33B
$23.4M 1.21%
267,270
+117,878
+79% +$11.2M
MC icon
27
Moelis & Co
MC
$5.12B
$22.6M 1.17%
668,614
-108,491
-14% -$4.54M
CUTR
28
DELISTED
Cutera, Inc.
CUTR
$21.8M 1.12%
477,833
+17,601
+4% +$803K
ACAD icon
29
Acadia Pharmaceuticals
ACAD
$4.8B
$21.8M 1.12%
1,329,626
+468,877
+54% +$7.59M
JACK icon
30
Jack in the Box
JACK
$291M
$21.3M 1.1%
287,087
– –
BPMC
31
DELISTED
Blueprint Medicines
BPMC
$21M 1.08%
+318,574
New +$20.5M
RPD icon
32
Rapid7
RPD
$773M
$20.9M 1.08%
486,797
-35,694
-7% -$2.2M
TMDX icon
33
Transmedics
TMDX
$3.02B
$20.7M 1.07%
494,926
+97,361
+24% +$4.23M
REPL icon
34
Replimune Group
REPL
$1.44B
$19.6M 1.01%
1,136,586
+43,263
+4% +$825K
UTHR icon
35
United Therapeutics
UTHR
$21B
$19.5M 1.01%
93,253
-66,840
-42% -$14.9M
KTOS icon
36
Kratos Defense & Security Solutions
KTOS
$9.03B
$19.5M 1.01%
1,919,534
+247,198
+15% +$3.31M
CRS icon
37
Carpenter Technology
CRS
$23.2B
$19.5M 1.01%
625,868
+162
+0% +$5.36K
CELH icon
38
Celsius Holdings
CELH
$8B
$19.3M 0.99%
+637,431
New +$20M
FWRD icon
39
Forward Air
FWRD
$551M
$19M 0.98%
210,798
+60
+0% +$5.89K
NOG icon
40
Northern Oil and Gas
NOG
$2.76B
$18.9M 0.98%
691,302
+671,052
+3,314% +$18.9M
MTDR icon
41
Matador Resources
MTDR
$7.39B
$18.6M 0.96%
380,877
+32,197
+9% +$1.74M
ITGR icon
42
Integer Holdings
ITGR
$4.27B
$18.6M 0.96%
298,641
-39
-0% -$2.62K
NEO icon
43
NeoGenomics
NEO
$2.24B
$18.4M 0.95%
2,139,579
+926,226
+76% +$9.2M
DCGO icon
44
DocGo
DCGO
$40M
$18.4M 0.95%
1,854,392
+11,153
+0.6% +$101K
AHCO icon
45
AdaptHealth
AHCO
$856M
$18.1M 0.93%
964,246
+941,018
+4,051% +$19.3M
ACDC icon
46
ProFrac Holding
ACDC
$932M
$18M 0.93%
1,181,931
+306,933
+35% +$5.52M
ISEE
47
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.3M 0.89%
+962,907
New +$12.6M
AMLX icon
48
Amylyx Pharmaceuticals
AMLX
$3.78B
$16.9M 0.87%
+601,226
New +$15M
ATRC icon
49
AtriCure
ATRC
$2.67B
$16.8M 0.86%
428,631
+200
+0% +$9.15K
CYTK icon
50
Cytokinetics
CYTK
$10.3B
$16.5M 0.85%
340,610
+196,300
+136% +$9.45M
1
2
3 4 5

Similar funds

AP
Altarock Partners West Palm Beach, Florida $4.24B AUM 4.82% 1-Year Est. Return
QWP
Quotient Wealth Partners Dallas, Texas $4.24B AUM 17.81% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
SCA
Snowden Capital Advisors New York $4.23B AUM 29.95% 1-Year Est. Return
MA
Marshfield Associates Washington, District of Columbia $4.26B AUM 12.94% 1-Year Est. Return
TFM
Trian Fund Management New York $4.23B AUM 31.93% 1-Year Est. Return
IAA
Independent Advisor Alliance Charlotte, North Carolina $4.27B AUM 45.92% 1-Year Est. Return
CAM
Contour Asset Management New York $4.22B AUM 26.55% 1-Year Est. Return

Emerald Advisers's Q3 2022 Portfolio in Review

As of Q3 2022, Emerald Advisers held 264 positions worth $1.94B, down 0.32% from $1.94B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Emerald Advisers's Q3 2022 filing shows 14 new, 88 increased, 101 reduced and 15 closed positions. Its largest new stake was Blueprint Medicines: 318,574 shares worth $21M. The largest sale was Biohaven Pharmaceutical Holding Company Ltd., an estimated $24.9M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 26% a quarter earlier, followed by Industrials and Consumer Discretionary.

  • Emerald Advisers's largest Q3 2022 buy was Blueprint Medicines: 318,574 shares worth $21M.
  • Emerald Advisers added most to AdaptHealth in Q3 2022, an estimated $19.3M increase.
  • Emerald Advisers's biggest Q3 2022 reduction was Avient, cutting an estimated $21.7M.
  • Emerald Advisers fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2022, selling an estimated $24.9M.
  • Emerald Advisers's ten largest holdings make up 18% of its $1.94B portfolio in Q3 2022.
  • Emerald Advisers opened 14 new positions and closed 15 in Q3 2022.
  • Emerald Advisers's portfolio value fell 0.32% quarter-over-quarter to $1.94B.

Based on Emerald Advisers's 13F filing for Q3 2022, filed 25 Oct 2022.